A Phase II, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects With Endometriosis.

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo- and Active-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects With Endometriosis.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2013

At a glance

  • Drugs Elagolix (Primary) ; Leuprorelin
  • Indications Endometriosis; Pelvic pain
  • Focus Therapeutic Use
  • Acronyms TULIP-PETAL
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 26 Jun 2012 Results assessing the effects of treatment on BMD presented at the 94th Annual Meeting of the Endocrine Society.
    • 03 Feb 2012 Company (Abbott Laboratories) added as reported by ClinicalTrials.gov.
    • 03 Feb 2012 Actual patient number is 174 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top